The Efficacy of Adductor-Canal-Block (ACB) in Patients After Anterior Cruciate Ligament (ACL) Reconstruction
NCT ID: NCT01212666
Last Updated: 2012-09-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
50 participants
INTERVENTIONAL
2010-05-31
2012-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Adductor-Canal-Block, Ropivacain
25 patients. ACB. 30 mL Ropivacain 7,5 mg/mL. Ultrasound-guided application.
Ropivacain
Ultrasound-guided ACB; 30 mL Ropivacain 7,5 mg/mL. Single dose.
Adductor Canal Block, Placebo (saline)
25 patients. ACB. 30 mL Saline. Ultrasound-guided application.
Saline
Ultrasound-guided Adductor Canal Block; 30 mL Saline. Single dose.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ropivacain
Ultrasound-guided ACB; 30 mL Ropivacain 7,5 mg/mL. Single dose.
Saline
Ultrasound-guided Adductor Canal Block; 30 mL Saline. Single dose.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Reconstruction of Anterior Cruciate Ligament
* Written consent
* ASA I-II
* BMI 19-35
Exclusion Criteria
* Allergic reactions toward drugs used in the trial
* Pregnancy
* Abuse of alcohol/drugs
* Daily opioid intake
* Infection at injection site
* Can not be mobilised to 5 meters of walk; pre-surgery
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Glostrup University Hospital, Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Malene Espelund
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Malene Espelund, MD
Role: PRINCIPAL_INVESTIGATOR
Glostrup University Hospital, Copenhagen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Anaesthesiology, Glostrup University Hospital
Copenhagen, Glostrup, Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Espelund M, Fomsgaard JS, Haraszuk J, Mathiesen O, Dahl JB. Analgesic efficacy of ultrasound-guided adductor canal blockade after arthroscopic anterior cruciate ligament reconstruction: a randomised controlled trial. Eur J Anaesthesiol. 2013 Jul;30(7):422-8. doi: 10.1097/EJA.0b013e328360bdb9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SM1-ME-10
Identifier Type: -
Identifier Source: org_study_id